This Book >>

  • 360pp. Published March 2016
  • Scientific Research Publishing, Inc.,USA
  • Category: Medicine & Healthcare
  • ISBN: 978-1-61896-181-5
  • (Hardcover) USD 89.00
  • ISBN: 978-1-61896-180-8
  • (Paperback) USD 69.00
Authors/Editors Price: 40% off
Buy at: bookorder@scirp.org

Connect with SCIRP >>

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)
Home > Books > Advances in Alzheimer's Disease
Advances in Alzheimer's Disease
  • Description
  • Author(s) Information

Alzheimer’s disease (AD), also known as Alzheimer disease, accounts for 60% to 70% of cases of dementia. It is a chronic neurodegenerative disease that usually starts slowly and gets worse over time. The most common early symptom is difficulty in remembering recent events (short-term memory loss). As the disease advances, symptoms include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, not managing self care and behavioral. As a person’s condition declines, they often withdraw from family and society. Gradually, bodily functions are lost, ultimately leading to death. Although the speed of progression can vary, the average life expectancy following diagnosis is three to nine years.

 

In the present book, ten typical literatures about Alzheimer’s disease published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, neurology, genetics, ect. We hope this book can demonstrate advances in Alzheimer’s disease as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    A Meta-Analysis of Prospective Studies on the Role of Physical Activity and the Prevention of Alzheimer’s Disease in Older Adults
  • Chapter 2
    Immune Responses in Rapidly Progressive Dementia: A Comparative Study of Neuroinflammatory Markers in Creutzfeldt-Jakob Disease, Alzheimer’s Disease and Multiple Sclerosis
  • Chapter 3
    Lifetime Expectancy and Quality-Adjusted Life-Year in Alzheimer’s Disease with and without Cerebrovascular Disease: Effects of Nursing Home Replacement and Donepezil Administration – A Retrospective Analysis in the Tajiri Project
  • Chapter 4
    SNAP-25 is a Promising Novel Cerebrospinal Fluid Biomarker for Synapse Degeneration in Alzheimer ’s Disease
  • Chapter 5
    Alzheimer’s Disease Assessment Scale–Cognitive Subscale Variants in Mild Cognitive Impairment and Mild Alzheimer’s Disease: Change Over Time and the Effect of Enrichment Strategies
  • Chapter 6
    Assessing THK523 Selectivity for Tau Deposits in Alzheimer’s Disease and Non-Alzheimer’s Disease Tauopathies
  • Chapter 7
    Evidence That the Presynaptic Vesicle Protein CSPalpha is a Key Player in Synaptic Degeneration and Protection in Alzheimer’s Disease
  • Chapter 8
    Platelet Dysfunction in Hypercholesterolemia Mice, Two Alzheimer’s Disease Mouse Models and in Human Patients with Alzheimer’s Disease
  • Chapter 9
    Which Medical and Social Decision Topics Are Important after Early Diagnosis of Alzheimer’s Disease from the Perspectives of People with Alzheimer’s Disease, Spouses and Professionals?
  • Chapter 10
    Potential Repurposing of Oncology Drugs for the Treatment of Alzheimer’s Disease
Readership: Students, academics, teachers and other people attending or interested in Advances in Alzheimer's Disease
comments powered by Disqus